Catalent, the global leader in enabling biopharma, cell, gene and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, ha unveiled a multi-year $350 million investment at its facility in Bloomington, IN, to expand biologics drug substance and drug product manufacturing capabilities. The project will serve the industry’s robust biologics pipeline across various modalities with new bioreactors, syringe filling lines, and addi...